Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus safety study in epilepsy associated with focal cortical dysplasia type II
jRCTs031190157Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sirolimus in Focal Cortical Dysplasia Type 2 (FCD2) and epilepsy, sponsored by Nobelpharma Co., Ltd. Primary endpoint: adverse event. Started Dec 2019; status: completed.
02
Drugs
sirolimus
03
Conditions
Focal Cortical Dysplasia Type 2 (FCD2)epilepsy
Beyond the preview
Go deeper on jRCTs031190157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190157.